Biomarker Testing for Risk Assessment of Patients Suspected of Having Prostate Cancer

Gerald Andriole, MD presents a historical perspective on risk assessment workflow in patients suspected of having prostate cancer, and discusses how pre-biopsy biomarker tests can address clinical challenges and unmet needs.

Dr Andriole shares insight into how he incorporates pre-biopsy biomarker tests into prostate cancer risk assessment in his clinical practice.

A brief commentary on how clinical validity (CV) and clinical utility (CU) are measured for pre-biopsy biomarker tests in patients suspected of having prostate cancer, followed by a focused discussion on the available tests in the space.

An expert urologist summarizes the available CV and CU data for the various pre-biopsy biomarker test options, and opines on how use of these tests might impact patient risk stratification, subsequent management, and/or health outcomes.

Dr Andriole shares remaining unmet needs in prostate cancer risk assessment and shares his hopes for the future.